Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership

We recently published 11 Best Cancer Stocks to Buy Right Now. Incyte Corporation stands fourth on our list.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and inflammatory diseases, best known for Jakafi (ruxolitinib), a leading treatment for myelofibrosis and polycythemia vera. Its oncology portfolio also includes MONJUVI for lymphoma, PEMAZYRE for cholangiocarcinoma, ZYNYZ for Merkel cell carcinoma, and NIKTIMVO for chronic graft-versus-host disease, along with Opzelura for inflammatory skin conditions.

In Q2 2025, Jakafi delivered $764 million in revenue, an 8% year-over-year increase, prompting the company to raise full-year sales guidance to $3.0–3.05 billion. Strong demand and supportive healthcare policies have reinforced Jakafi’s growth, driving Incyte Corporation (NASDAQ:INCY)’s overall financial performance.

The business is expanding its precision medicine efforts through a global partnership with QIAGEN, developing a companion diagnostic for mutant calreticulin (mutCALR) to better identify patients for its investigational therapy INCA033989 in rare blood cancers.

Incyte Corporation (NASDAQ:INCY) reported positive Phase 2 results for povorcitinib, an oral JAK1 inhibitor for chronic spontaneous urticaria, underscoring diversification into immunology and dermatology. The corporation is also advancing a KRAS G12D inhibitor for pancreatic cancer, with potential as both a standalone and combination therapy.

Looking ahead, the firm expects 18+ clinical milestones in 2025, including four potential product launches, highlighting aggressive R&D investment across oncology and immune-related conditions.

While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.